Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals has opened registration for an investor webinar to be held on 27 January 2026, where senior executives will discuss the company’s Quarterly Activity Report, 4C Quarterly Cash Flow Report and provide an update on its recently approved Sofdra (sofpironium) 12.45% topical gel for primary axillary hyperhidrosis. The event underlines Botanix’s efforts to increase transparency with investors and highlight the commercial progress and strategic significance of Sofdra, which is central to the company’s positioning in the dermatology market.
The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix, focused on treatments for skin conditions. The company has secured FDA approval for Sofdra, a topical gel for primary axillary hyperhidrosis, representing the first and only new chemical entity approved in the US for this socially challenging excessive underarm sweating disorder.
Average Trading Volume: 4,687,909
Technical Sentiment Signal: Sell
Current Market Cap: A$255.9M
See more data about BOT stock on TipRanks’ Stock Analysis page.